X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

TCRX

Closed

Tscan Therapeutics Inc

1.43
-0.02 (-1.38%)
Last Update: 01 Jul 2025 23:03:00
Yesterday: 1.45
Day's Range: 1.43 - 1.54
Send
When Written:
 
2.02
TScan Therapeutics is a biotechnology company that is developing a novel T-cell receptor (TCR) therapy platform for the treatment of cancer. The company's proprietary technology platform is based on the identification of unique TCRs that can recognize and target cancer cells. TScan's approach is focused on developing personalized therapies that are tailored to individual patients based on their specific tumor antigens. The company's lead product candidate, TSC-100, is currently in preclinical development for the treatment of solid tumors. TScan was founded in 2018 and is headquartered in Waltham, Massachusetts. The company has raised over $100 million in funding from investors including Novartis, GV (formerly Google Ventures), and Longwood Fund.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X